

Laura E Targownik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4486507/publications.pdf>

Version: 2024-02-01

220
papers

7,965
citations

50170

46
h-index

54797

84
g-index

225
all docs

225
docs citations

225
times ranked

8574
citing authors

#	ARTICLE	IF	CITATIONS
1	What Is a Flare? The Manitoba Living With IBD Study. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 862-869.	0.9	5
2	Pregnancy and Live Birth Rates Over Time in Women With Inflammatory Bowel Disease: A Population-Based Cohort Study. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 184-191.	0.1	1
3	Cost-Effectiveness of Tight Control for Crohn's Disease With Adalimumab-Based Treatment: Economic Evaluation of the CALM Trial From a Canadian Perspective. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 169-176.	0.1	5
4	Is the attenuated humoral response to COVID-19 vaccination in anti-TNF users relevant?. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 280-282.	3.7	8
5	The association of efficacy, optimism, uncertainty and health anxiety with inflammatory bowel disease activity. <i>Journal of Psychosomatic Research</i> , 2022, 154, 110719.	1.2	4
6	Self-reported flares among people living with inflammatory bowel disease are associated with stress and worry but not associated with recent diet changes: The Manitoba Living with IBD Study. <i>Journal of Parenteral and Enteral Nutrition</i> , 2022, 46, 1686-1698.	1.3	5
7	A158 COMPARING CORTIMENTA® AND PREDNISONE IN ULCERATIVE COLITIS: A POPULATION-BASED STUDY OF OUTCOMES. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 33-35.	0.1	0
8	Earlier Anti-TNF Initiation Leads to Long-term Lower Health Care Utilization in Crohn's Disease but Not in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2607-2618.e14.	2.4	13
9	AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. <i>Gastroenterology</i> , 2022, 162, 1334-1342.	0.6	86
10	Association Between Change in Inflammatory Aspects of Diet and Change in IBD-related Inflammation and Symptoms Over 1 Year: The Manitoba Living With IBD Study. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 190-202.	0.9	13
11	Utility of the MARS-5 in Assessing Medication Adherence in IBD. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 317-324.	0.9	12
12	Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study. <i>Gut</i> , 2021, 70, 499-510.	6.1	127
13	Anxiety and Depression Leads to Anti-Tumor Necrosis Factor Discontinuation in Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1200-1208.e1.	2.4	18
14	Gastroenterologist Consultation Is Uncommon but Associated with Improved Care Among IBD Patients Presenting to Emergency Departments in Winnipeg Hospitals. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, 57-64.	0.1	2
15	Crohn's and Colitis Canada's 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S10-S19.	0.1	2
16	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBD. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S34-S39.	0.1	2
17	OUP accepted manuscript. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S20-S26.	0.1	0
18	OUP accepted manuscript. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S40-S45.	0.1	4

#	ARTICLE	IF	CITATIONS
19	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Health Care Delivery During the Pandemic and the Future Model of Inflammatory Bowel Disease Care. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S61-S67.	0.1	7
20	OUP accepted manuscript. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S1-S9.	0.1	5
21	OUP accepted manuscript. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S27-S33.	0.1	3
22	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Mental Health and Quality of Life. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S46-S53.	0.1	9
23	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines' Biology, Current Evidence and Recommendations. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S54-S60.	0.1	9
24	A172 THE ASSOCIATION OF EFFICACY, OPTIMISM, UNCERTAINTY AND HEALTH ANXIETY IN INFLAMMATORY BOWEL DISEASE ACTIVITY OVER TIME. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, 183-184.	0.1	0
25	Trends in Corticosteroid Use During the Era of Biologic Therapy: A Population-Based Analysis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1284-1293.	0.2	12
26	A155 REAL-WORLD USE OF CORTICOSTEROIDS IN ULCERATIVE COLITIS: A POPULATION-BASED STUDY. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, 161-162.	0.1	0
27	Inflammatory Bowel Disease Increases the Risk of Venous Thromboembolism in Children: A Population-Based Matched Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 2031-2040.	0.6	20
28	Continued 5-ASA use after initiation of anti-TNF or immunomodulator confers no benefit in IBD: a population-based study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 814-832.	1.9	7
29	Editorial: 5-ASA in IBD patients on biologics' stop or continue? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 845-845.	1.9	0
30	The complex relationship between diet, symptoms, and intestinal inflammation in persons with inflammatory bowel disease: The Manitoba Living With IBD Study. <i>Journal of Parenteral and Enteral Nutrition</i> , 2021, , .	1.3	4
31	Trends of Utilization of Tumor Necrosis Factor Antagonists in Children With Inflammatory Bowel Disease: A Canadian Population-Based Study. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 134-138.	0.9	10
32	A Population-Based Study of Combination vs Monotherapy of Anti-TNF in Persons With IBD. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 150-157.	0.9	4
33	Extreme restriction design as a method for reducing confounding by indication in pharmacoepidemiologic research. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 26-34.	0.9	12
34	Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. <i>Gut</i> , 2020, 69, 274-282.	6.1	145
35	The Cost of Use of the Emergency Department by Persons With Inflammatory Bowel Disease Living in a Canadian Health Region: A Retrospective Population-Based Study. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, 135-140.	0.1	3
36	Cannabis Use in Persons With Inflammatory Bowel Disease and Vulnerability to Substance Misuse. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1401-1406.	0.9	16

#	ARTICLE	IF	CITATIONS
37	A population-based analysis of antidiabetic medications in four Canadian provinces: Secular trends and prescribing patterns. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 86-92.	0.9	10
38	Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population-Based Analysis. <i>American Journal of Gastroenterology</i> , 2020, 115, 128-137.	0.2	39
39	Re-cherchez la Femme: A Second Look at Women in Gastroenterology in Canada. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, 55-56.	0.1	1
40	Time trends and predictors of laboratory-confirmed recurrent and severe <i>Clostridioides difficile</i> infections in Manitoba: a population-based study. <i>CMAJ Open</i> , 2020, 8, E737-E746.	1.1	1
41	What Constitutes Frailty In Inflammatory Bowel Disease?. <i>Gastroenterology</i> , 2020, 159, 1993.	0.6	0
42	Cost-effectiveness analysis of a fecal microbiota transplant center for treating recurrent <i>C.difficile</i> infection. <i>Journal of Infection</i> , 2020, 81, 758-765.	1.7	9
43	P043 FOCUSING ON THE FUTURE: REDUCING BARRIERS AND IMPROVING ACCESS TO IBD SPECIALTY CARE ACROSS CANADA. <i>Inflammatory Bowel Diseases</i> , 2020, 26, S63-S63.	0.9	1
44	IMAGINE Network's Mind And Gut Interactions Cohort (MAGIC) Study: a protocol for a prospective observational multicentre cohort study in inflammatory bowel disease and irritable bowel syndrome. <i>BMJ Open</i> , 2020, 10, e041733.	0.8	5
45	Effectiveness of Dose De-escalation of Biologic Therapy in Inflammatory Bowel Disease: A Systematic Review. <i>American Journal of Gastroenterology</i> , 2020, 115, 1768-1774.	0.2	11
46	Providing Hospitalized Ulcerative Colitis Patients With Practice Guidelines Improves Patient-Reported Outcomes. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 4, 131-136.	0.1	4
47	Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1354-1363.	0.6	38
48	Su1805 THE LONG-TERM CORTICOSTEROID SPARING EFFECT OF ANTI-TNF THERAPY IN A REAL WORLD CROHN'S DISEASE COHORT. <i>Gastroenterology</i> , 2020, 158, S-655.	0.6	1
49	Dose Augmentation of Tumor Necrosis Factor Inhibitors is Frequently Performed in Persons With Inflammatory Bowel Disease in the Absence of Objective Evidence of Active Inflammation. <i>Journal of Clinical Gastroenterology</i> , 2020, Publish Ahead of Print, 602-608.	1.1	1
50	Herpes Zoster Infection and Herpes Zoster Vaccination in a Population-Based Sample of Persons With IBD: Is There Still an Unmet Need?. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 532-540.	0.9	18
51	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1-13.	0.9	73
52	Association Between IBD Disability and Reduced Work Productivity (Presenteeism): A Population-Based Study in Manitoba, Canada. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 352-359.	0.9	24
53	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1680-1713.	2.4	32
54	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, e1-e34.	0.1	32

#	ARTICLE	IF	CITATIONS
55	Editorial: understanding sex and gender dimorphism in chronic diseases may improve outcomes. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 603-604.	1.9	2
56	Direct cost of health care for individuals with community associated <i>Clostridium difficile</i> infections: A population-based cohort study. <i>PLoS ONE</i> , 2019, 14, e0224609.	1.1	6
57	Health Care Indicators of Moderate to Severe IBD and Subsequent IBD-Related Disability: A Longitudinal Study. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1996-2005.	0.9	8
58	The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1718-1728.	0.9	31
59	The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, S17-S33.	0.1	63
60	Events Within the First Year of Life, but Not the Neonatal Period, Affect Risk for Later Development of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2019, 156, 2190-2197.e10.	0.6	53
61	A1 LONGITUDINAL CHANGES IN THE DIRECT COST OF IBD CARE IN THE BIOLOGIC ERA. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, 1-3.	0.1	6
62	Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. <i>Gastroenterology</i> , 2019, 156, 1345-1353.e4.	0.6	273
63	Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1788-1798.e2.	2.4	23
64	The Clinician's Guide to Proton Pump Inhibitor Related Adverse Events. <i>Drugs</i> , 2019, 79, 715-731.	4.9	29
65	The Impact of Inflammatory Bowel Disease in Canada 2018: IBD in Seniors. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, S68-S72.	0.1	29
66	The Inflammatory Bowel Disease Symptom Inventory: A Patient-report Scale for Research and Clinical Application. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1277-1290.	0.9	27
67	Management of Biological Therapy Before Elective Inflammatory Bowel Disease Surgeries. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1613-1620.	0.9	4
68	179€fCost-Effectiveness Analysis of Starting a Fecal Microbiota Transplantation (FMT) Unit for the Treatment of Recurrent <i>C. difficile</i> Infection Compared With Antibiotic Therapy. <i>American Journal of Gastroenterology</i> , 2019, 114, S110-S110.	0.2	1
69	The Clinician's Guide to Proton-Pump Inhibitor Discontinuation. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 553-559.	1.1	3
70	The Impact of Inflammatory Bowel Disease in Canada 2018: A Scientific Report from the Canadian Gastro-Intestinal Epidemiology Consortium to Crohn's and Colitis Canada. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, S1-S5.	0.1	46
71	Trends and Predictors of <i>Clostridium difficile</i> Infection among Children: A Canadian Population-Based Study. <i>Journal of Pediatrics</i> , 2019, 206, 20-25.	0.9	13
72	Inflammatory bowel disease and new-onset psychiatric disorders in pregnancy and post partum: a population-based cohort study. <i>Gut</i> , 2019, 68, 1597-1605.	6.1	29

#	ARTICLE	IF	CITATIONS
73	Reply to Letter to Editor of Dr. Elia. Inflammatory Bowel Diseases, 2019, 25, e9-e9.	0.9	0
74	Appropriateness of Biologics in the Management of Crohn's Disease Using RAND/UCLA Appropriateness Methodology. Inflammatory Bowel Diseases, 2019, 25, 328-335.	0.9	7
75	Reply. Gastroenterology, 2018, 154, 256-257.	0.6	0
76	Editorial: Non-breaking news! High-dose PPIs likely do not cause fractures. Alimentary Pharmacology and Therapeutics, 2018, 47, 137-137.	1.9	5
77	Independent Validation of a Self-Report Version of the IBD Disability Index (IBDDI) in a Population-Based Cohort of IBD Patients. Inflammatory Bowel Diseases, 2018, 24, 766-774.	0.9	22
78	Discontinuing Long-Term PPI Therapy: Why, With Whom, and How?. American Journal of Gastroenterology, 2018, 113, 519-528.	0.2	39
79	A34 TRENDS AND PREDICTORS OF CLOSTRIDIUM DIFFICILE INFECTION AMONG THE CHILDREN OF MANITOBA: A POPULATION-BASED STUDY. Journal of the Canadian Association of Gastroenterology, 2018, 1, 57-58.	0.1	0
80	Rural and urban disparities in the care of Canadian patients with inflammatory bowel disease: a population-based study. Clinical Epidemiology, 2018, Volume 10, 1613-1626.	1.5	48
81	A105 CANADIAN WOMEN WITH IBD ARE MORE LIKELY TO GIVE BIRTH TO LOW BIRTH WEIGHT INFANTS. Journal of the Canadian Association of Gastroenterology, 2018, 1, 159-160.	0.1	0
82	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. Journal of the Canadian Association of Gastroenterology, 2018, 1, 141-154.	0.1	10
83	Persistence With Immunomodulator Monotherapy Use And Incidence of Therapeutic Ineffectiveness Among Users of Immunomodulator Monotherapy in IBD. American Journal of Gastroenterology, 2018, 113, 1206-1216.	0.2	7
84	Sa1073 - Time Trends of Laboratory Confirmed Clostridium Difficile Infections in an Entire Province Suggest an Increasing Shift to Community Acquired Infections and Younger Age of Acquiring Infections. Gastroenterology, 2018, 154, S-230-S-231.	0.6	1
85	Mo1871 - Direct Costs of Care Among Patients with Inflammatory Bowel Disease before and after Initiation of Anti-TNF Therapy. Gastroenterology, 2018, 154, S-833.	0.6	3
86	Editorial: let's take a break from studying the PPI-fracture association. Alimentary Pharmacology and Therapeutics, 2018, 47, 1543-1544.	1.9	4
87	Living With Inflammatory Bowel Disease: Protocol for a Longitudinal Study of Factors Associated With Symptom Exacerbations. JMIR Research Protocols, 2018, 7, e11317.	0.5	11
88	Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis. Clinical Gastroenterology and Hepatology, 2017, 15, 1061-1070.e1.	2.4	32
89	Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases. American Journal of Gastroenterology, 2017, 112, 1120-1134.	0.2	241
90	Coping with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 1247-1256.	0.9	7

#	ARTICLE	IF	CITATIONS
91	Higher Incidence of Clostridium difficile Infection Among Individuals With Inflammatory Bowel Disease. Gastroenterology, 2017, 153, 430-438.e2.	0.6	109
92	Herpes Zoster Infection and Herpes Zoster Vaccination in IBD: A Need for Improvement in Vaccination Rates. Gastroenterology, 2017, 152, S971-S972.	0.6	0
93	What are the Most Common Symptoms Reported in a Self-Reported Flare of IBD? the Manitoba Living with IBD Study. Gastroenterology, 2017, 152, S376-S377.	0.6	0
94	Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 858-865.	0.9	25
95	The Prevalence and Predictors of Anti-TNF Failure in a Population based Sample of Persons with IBD. Gastroenterology, 2017, 152, S360-S361.	0.6	0
96	Workplace Accommodation for Persons With IBD: What Is Needed and What Is Accessed. Clinical Gastroenterology and Hepatology, 2017, 15, 1589-1595.e4.	2.4	11
97	Independent Validation of a Self-Report Version of the IBD Disability Index (IBDDI) in a Population-Based Cohort of IBD Patients. Gastroenterology, 2017, 152, S25.	0.6	4
98	A Survey of Workplace Accommodations among Persons with IBD. Gastroenterology, 2017, 152, S123-S124.	0.6	0
99	A Survey of Patient Views of Factors Producing Symptom Exacerbations in the Living with IBD Study. Gastroenterology, 2017, 152, S365.	0.6	0
100	No Increase in Immunomodulator Use in Combination with Anti-TNF Therapy in the Post Sonic ERA. Gastroenterology, 2017, 152, S400.	0.6	1
101	What is a Flare of IBD?: The Manitoba Living with IBD Study. Gastroenterology, 2017, 152, S27.	0.6	0
102	Preferences for Care for Active Symptoms of IBD in a Population Based Sample. Gastroenterology, 2017, 152, S365.	0.6	1
103	Association between IBD Disability and Reduced Work Productivity (Presenteeism): A Population-Based Study in Manitoba, Canada. Gastroenterology, 2017, 152, S375.	0.6	0
104	Evaluation of Knowledge Translation Resources for Patients about IBD and its Management. Gastroenterology, 2017, 152, S799-S800.	0.6	0
105	Concomitant Immunomodulator is Associated with a Decreased Risk of Anti-TNF Discontinuation and Substitution: A Population Based Study. Gastroenterology, 2017, 152, S970.	0.6	4
106	Studies Using Hospital Discharge Databases may Underestimate Occurrence of Clostridium Difficile Infections Among Hospitalized Individuals with Inflammatory Bowel Disease. Gastroenterology, 2017, 152, S979.	0.6	0
107	Evidence of Bidirectional Associations Between Perceived Stress and Symptom Activity. Inflammatory Bowel Diseases, 2017, 23, 473-483.	0.9	57
108	Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD. Inflammatory Bowel Diseases, 2017, 23, 409-420.	0.9	34

#	ARTICLE	IF	CITATIONS
109	Maternal Infections That Would Warrant Antibiotic Use Antepartum or Peripartum Are Not a Risk Factor for the Development of IBD. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 635-640.	0.9	11
110	Health Care Services in IBD. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1461-1469.	0.9	15
111	The Economics of Inflammatory Bowel Disease. <i>Clinical Gastroenterology</i> , 2017, , 345-355.	0.0	0
112	Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure. <i>American Journal of Gastroenterology</i> , 2017, 112, 95-101.	0.2	62
113	Surgical Rates for Crohn's Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study. <i>American Journal of Gastroenterology</i> , 2017, 112, 1840-1848.	0.2	140
114	Rural and Urban Residence During Early Life is Associated with Risk of Inflammatory Bowel Disease: A Population-Based Inception and Birth Cohort Study. <i>American Journal of Gastroenterology</i> , 2017, 112, 1412-1422.	0.2	88
115	Hospital discharge abstracts have limited accuracy in identifying occurrence of <i>Clostridium difficile</i> infections among hospitalized individuals with inflammatory bowel disease: A population-based study. <i>PLoS ONE</i> , 2017, 12, e0171266.	1.1	8
116	<i>Clostridium difficile</i> Infections Among Hospitalized Individuals With IBD. <i>American Journal of Gastroenterology</i> , 2017, 112, S340-S342.	0.2	0
117	Assessing the Relationship between Sources of Stress and Symptom Changes among Persons with IBD over Time: A Prospective Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-8.	0.8	18
118	A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 974-984.	1.9	126
119	Estimates of Disease Course in Inflammatory Bowel Disease Using Administrative Data: A Population-level Study. <i>Journal of Crohn's and Colitis</i> , 2016, 11, jjw201.	0.6	8
120	Failure to Account for Immortal Person Time Likely Accounts for the Apparent Reduction in Surgery Among Natalizumab Users. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 776.	2.4	0
121	18 Emergency Department Use by Persons With IBD; A Population Based Study. <i>Gastroenterology</i> , 2016, 150, S6.	0.6	0
122	164 Dietary Lactose Consumption Is Associated With Both Increased Symptoms and Intestinal Inflammation in IBD. <i>Gastroenterology</i> , 2016, 150, S41-S42.	0.6	3
123	Ustekinumab for the treatment of Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 989-994.	1.4	7
124	Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis. <i>JAMA Internal Medicine</i> , 2016, 176, 1464.	2.6	87
125	Performance of administrative case definitions for depression and anxiety in inflammatory bowel disease. <i>Journal of Psychosomatic Research</i> , 2016, 89, 107-113.	1.2	50
126	Understanding Work Experiences of People with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1688-1697.	0.9	24

#	ARTICLE	IF	CITATIONS
127	Validating a Measure of Patient Self-efficacy in Disease Self-management Using a Population-based IBD Cohort. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2165-2172.	0.9	23
128	Predictors of Emergency Department Use by Persons with Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2907-2916.	0.9	39
129	Rates and Reasons for Nonuse of Prescription Medication for Inflammatory Bowel Disease in a Referral Clinic. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 919-924.	0.9	11
130	Emerging issues in the medical management of Crohn's disease. <i>Current Opinion in Gastroenterology</i> , 2016, 32, 103-109.	1.0	4
131	Mo1797 Maternal Antibiotic Use Antepartum or Peripartum Period Is Not Associated With the Development of IBD in offspring: A Population Based Analysis. <i>Gastroenterology</i> , 2016, 150, S778-S779.	0.6	0
132	1124 There Is No Decrease in the Mortality From IBD Associated Colorectal Cancers Over 25 Years: A Population Based Analysis. <i>Gastroenterology</i> , 2016, 150, S226-S227.	0.6	6
133	A Multicenter Observational Study of Incretin-based Drugs and Heart Failure. <i>New England Journal of Medicine</i> , 2016, 374, 1145-1154.	13.9	191
134	Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. <i>BMJ</i> , The, 2016, 352, i581.	3.0	78
135	The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. <i>Gastroenterology</i> , 2016, 150, 734-757.e1.	0.6	373
136	Cesarean Section Delivery Is Not a Risk Factor for Development of Inflammatory Bowel Disease: A Population-based Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 50-57.	2.4	36
137	What Are Adults With Inflammatory Bowel Disease (IBD) Eating? A Closer Look at the Dietary Habits of a Population-Based Canadian IBD Cohort. <i>Journal of Parenteral and Enteral Nutrition</i> , 2016, 40, 405-411.	1.3	79
138	Reply. <i>Gastroenterology</i> , 2015, 149, 1634.	0.6	0
139	Characterization of Inflammatory Bowel Disease in Elderly Patients: A Review of Epidemiology, Current Practices and Outcomes of Current Management Strategies. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 327-333.	0.8	44
140	Patterns and Predictors of Long-term Nonuse of Medical Therapy Among Persons with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1615-1622.	0.9	13
141	Understanding and Avoiding Immortal-Time Bias in Gastrointestinal Observational Research. <i>American Journal of Gastroenterology</i> , 2015, 110, 1647-1650.	0.2	56
142	Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus. <i>Gastroenterology</i> , 2015, 148, 1035-1058.e3.	0.6	323
143	Health Care Use by a Population-Based Cohort of Children With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1302-1309.e3.	2.4	16
144	The Relationship Among Perceived Stress, Symptoms, and Inflammation in Persons With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2015, 110, 1001-1012.	0.2	123

#	ARTICLE	IF	CITATIONS
145	The Importance of Accounting for Immortal Time Bias in Pharmacoepidemiologic Analyses. <i>American Journal of Gastroenterology</i> , 2015, 110, 349.	0.2	4
146	Academic Performance among Children with Inflammatory Bowel Disease: A Population-Based Study. <i>Journal of Pediatrics</i> , 2015, 166, 1128-1133.	0.9	29
147	A Preliminary Study of DXA and QCT Derived Femur Cross-Section Stiffness. <i>Applied Mechanics and Materials</i> , 2015, 775, 415-419.	0.2	0
148	Predictors and risks for death in a population-based study of persons with IBD in Manitoba. <i>Gut</i> , 2015, 64, 1403-1411.	6.1	65
149	Are We Worried Enough About Selective Serotonin Receptor Inhibitors and Upper Gastrointestinal Bleeding?. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 51-54.	2.4	2
150	Immortal Time Bias: A Likely Alternate Explanation for the Purported Benefits of DXA Screening in Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1689.	0.2	1
151	Risk factors and management of osteoporosis in inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 168-174.	1.0	50
152	Prevalence of and Outcomes Associated with Corticosteroid Prescription in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 622-630.	0.9	49
153	Association Between Spring Season of Birth and Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 277-282.	2.4	15
154	Gastrointestinal symptoms before and during menses in healthy women. <i>BMC Women's Health</i> , 2014, 14, 14.	0.8	38
155	What is the role for bisphosphonates in IBD?. <i>Gut</i> , 2014, 63, 1369-1370.	6.1	3
156	Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. <i>Gut</i> , 2014, 63, 552-558.	6.1	154
157	The Prevalence and Predictors of Opioid Use in Inflammatory Bowel Disease: A Population-Based Analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1613-1620.	0.2	106
158	Low Prevalence of Disability Among Patients With Inflammatory Bowel Diseases a Decade After Diagnosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1330-1337.e2.	2.4	40
159	Sa1201 Development of an IBD Symptom Self-Report Scale for Research and Clinical Application. <i>Gastroenterology</i> , 2014, 146, S-228-S-229.	0.6	2
160	Su1348 The Non Use of IBD-Specific Prescription Medications in Patients With IBD. <i>Gastroenterology</i> , 2014, 146, S-443.	0.6	1
161	223 Patterns of Drug Avoidance in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2013, 144, S-48-S-49.	0.6	3
162	Inflammatory Bowel Disease Has a Small Effect on Bone Mineral Density and Risk for Osteoporosis. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 278-285.	2.4	45

#	ARTICLE	IF	CITATIONS
163	Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 274-283.	1.9	62
164	Infectious and Malignant Complications of TNF Inhibitor Therapy in IBD. <i>American Journal of Gastroenterology</i> , 2013, 108, 1835-1842.	0.2	97
165	Inflammatory bowel disease and the risk of osteoporosis and fracture. <i>Maturitas</i> , 2013, 76, 315-319.	1.0	46
166	The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. <i>Osteoporosis International</i> , 2013, 24, 1161-1168.	1.3	120
167	The association between proton pump inhibitor use and hip fracture cannot be explained by differences in dietary and lifestyle choices. <i>Evidence-Based Medicine</i> , 2013, 18, 38-39.	0.6	0
168	Inflammatory bowel disease and the risk of fracture after controlling for FRAX. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1007-1013.	3.1	27
169	Predictors of Academic Performance among Children with Inflammatory Bowel Disease: A Population-based Study. <i>American Journal of Gastroenterology</i> , 2013, 108, S555.	0.2	0
170	Prescribing proton pump inhibitors with clopidogrel. <i>BMJ, The</i> , 2012, 345, e4558-e4558.	3.0	4
171	The Relationship Between Proton Pump Inhibitor Use and Longitudinal Change in Bone Mineral Density: A Population-Based From the Canadian Multicentre Osteoporosis Study (CaMos). <i>American Journal of Gastroenterology</i> , 2012, 107, 1361-1369.	0.2	110
172	Longitudinal Change in Bone Mineral Density in a Population-Based Cohort of Patients with Inflammatory Bowel Disease. <i>Calcified Tissue International</i> , 2012, 91, 356-363.	1.5	23
173	The Epidemiology of Colectomy in Ulcerative Colitis: Results From a Population-Based Cohort. <i>American Journal of Gastroenterology</i> , 2012, 107, 1228-1235.	0.2	232
174	Gastrointestinal symptoms before and during menses in women with <scp>IBD</scp>. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 135-144.	1.9	36
175	Author's reply to Witham and colleagues. <i>BMJ, The</i> , 2012, 345, e5852-e5852.	3.0	0
176	Prescription Drug Use in IBD: A Population Based Study. <i>Gastroenterology</i> , 2011, 140, S-778-S-779.	0.6	0
177	The Risk of Early and Late Colectomy in Patients With Ulcerative Colitis: Results From a Population-Based Cohort. <i>Gastroenterology</i> , 2011, 140, S-113-S-114.	0.6	2
178	A Population-Based Study of Prevalence and Predictors of Hospitalization in UC. <i>Gastroenterology</i> , 2011, 140, S-780.	0.6	1
179	The relationship among proton pump inhibitors, bone disease and fracture. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 901-912.	1.0	18
180	Risk of Low Bone Mineral Density Associated With Psychotropic Medications and Mental Disorders in Postmenopausal Women. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 56-60.	0.7	51

#	ARTICLE	IF	CITATIONS
181	Proton Pump Inhibitors Are Associated with Decreased Bone Mineral Density. American Journal of Gastroenterology, 2011, 106, S405-S406.	0.2	1
182	The Relationship Between Inflammatory Bowel Disease and Bone Mineral Density. Results of a Population-based Study. American Journal of Gastroenterology, 2011, 106, S492.	0.2	2
183	Is Inflammatory Bowel Disease a Risk Factor for Fracture? An Analysis Using the Fracture Risk Assessment Tool (FRAX): 2011 ACG Presidential Poster. American Journal of Gastroenterology, 2011, 106, S431.	0.2	0
184	Immortal time bias and infliximab-related mortality and malignancy incidence. Gut, 2010, 59, 416-416.	6.1	3
185	Proton-Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density Loss. Gastroenterology, 2010, 138, 896-904.	0.6	227
186	Proton pump inhibitors and osteoporosis-related fractures. Cmaj, 2009, 180, 643-644.	0.9	1
187	Another bad break for proton-pump inhibitors?. Nature Reviews Rheumatology, 2009, 5, 478-480.	3.5	3
188	Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures. Maturitas, 2009, 64, 9-13.	1.0	35
189	Proton pump inhibitors and osteoporosis-related fractures. Cmaj, 2009, 180, 643-643.	0.9	1
190	Selective Serotonin Reuptake Inhibitors Are Associated With a Modest Increase in the Risk of Upper Gastrointestinal Bleeding. American Journal of Gastroenterology, 2009, 104, 1475-1482.	0.2	99
191	Comparing Resource Utilization and Gastrointestinal Outcomes in Patients Treated with Either Standard-Dose or High-Dose Proton Pump Inhibitors: A Matched Cohort Study. Digestive Diseases and Sciences, 2008, 53, 1519-1526.	1.1	5
192	Underutilization of gastroprotective strategies in aspirin users at increased risk of upper gastrointestinal complications. Alimentary Pharmacology and Therapeutics, 2008, 28, 88-96.	1.9	16
193	The Relative Efficacies of Gastroprotective Strategies in Chronic Users of Nonsteroidal Anti-inflammatory Drugs. Gastroenterology, 2008, 134, 937-944.e1.	0.6	109
194	Use of proton pump inhibitors and risk of osteoporosis-related fractures. Cmaj, 2008, 179, 319-326.	0.9	352
195	The Infusion Illusion. American Journal of Gastroenterology, 2008, 103, 3019-3021.	0.2	1
196	The Prevalence of and the Clinical and Demographic Characteristics Associated With High-Intensity Proton Pump Inhibitor Use. American Journal of Gastroenterology, 2007, 102, 942-950.	0.2	78
197	An Assessment of Endoscopic and Concomitant Management of Acute Variceal Bleeding at a Tertiary Care Centre. Canadian Journal of Gastroenterology & Hepatology, 2007, 21, 85-90.	1.8	12
198	The Role of Rapid Endoscopy for High-Risk Patients with Acute Nonvariceal Upper Gastrointestinal Bleeding. Canadian Journal of Gastroenterology & Hepatology, 2007, 21, 425-429.	1.8	62

#	ARTICLE	IF	CITATIONS
199	Pre-endoscopic PPI therapy reduces recurrent adverse outcomes in acute non-variceal upper gastrointestinal bleeding: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 344-345.	1.9	0
200	Differences in the management of Crohn's disease among experts and community providers, based on a national survey of sample case vignettes. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 1005-1018.	1.9	79
201	Intravenous Versus High-Dose Oral Proton Pump Inhibitor Therapy After Endoscopic Hemostasis of High-Risk Lesions in Patients with Acute Nonvariceal Upper Gastrointestinal Bleeding. <i>Digestive Diseases and Sciences</i> , 2007, 52, 1685-1690.	1.1	16
202	The Cost Effectiveness of Colonic Stenting As a Bridge to Curative Surgery in Patients with Acute Left-Sided Malignant Colonic Obstruction: A Canadian Perspective. <i>Gastrointestinal Endoscopy</i> , 2006, 63, AB98.	0.5	0
203	Trends in Management and Outcomes of Acute Nonvariceal Upper Gastrointestinal Bleeding: 1993-2003. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1459-1466.e1.	2.4	142
204	The Cost-Effectiveness of Colonic Stenting as a Bridge to Curative Surgery in Patients with Acute Left-Sided Malignant Colonic Obstruction: A Canadian Perspective. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2006, 20, 779-785.	1.8	39
205	The prevalence of risk factors for gastrointestinal complications and use of gastroprotection among persons hospitalized for cardiovascular disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 743-749.	1.9	12
206	Physicians' approaches to the use of gastroprotective strategies in low-risk non-steroidal anti-inflammatory drug users. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1365-1372.	1.9	12
207	Pre-endoscopic proton pump inhibitor therapy reduces recurrent adverse gastrointestinal outcomes in patients with acute non-variceal upper gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1247-1255.	1.9	29
208	Colonoscopic Screening for Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 2438.	3.8	5
209	Risk of Developing Colorectal Cancer Following a Negative Colonoscopy Examination. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2366.	3.8	375
210	Colorectal Cancer Risk Following a Negative Colonoscopy—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 2436.	3.8	0
211	Gastroprotective strategies among NSAID users: guidelines for appropriate use in chronic illness. <i>Canadian Family Physician</i> , 2006, 52, 1100-5.	0.1	16
212	Is Endoscopic Ultrasound (EUS) Appropriate for the Diagnosis of Perianal Fistula in Crohn's Disease (CD)? A Survey of North American Inflammatory Bowel Disease (IBD) Experts. <i>Gastrointestinal Endoscopy</i> , 2005, 61, AB275.	0.5	0
213	The Cost-Effectiveness of Hepatic Venous Pressure Gradient Monitoring in the Prevention of Recurrent Variceal Hemorrhage. <i>American Journal of Gastroenterology</i> , 2004, 99, 1306-1315.	0.2	35
214	The quality of published health economic analyses in digestive diseases: A systematic review and quantitative appraisal. <i>Gastroenterology</i> , 2004, 127, 403-411.	0.6	76
215	Colonic stent vs. emergency surgery for management of acute left-sided malignant colonic obstruction: a decision analysis. <i>Gastrointestinal Endoscopy</i> , 2004, 60, 865-874.	0.5	155
216	Endoscopic screening for esophageal varices in cirrhosis: Is it ever cost effective?. <i>Hepatology</i> , 2003, 37, 366-377.	3.6	137

#	ARTICLE	IF	CITATIONS
217	The Cost-Effectiveness of Cyclooxygenase-2 Selective Inhibitors in the Management of Chronic Arthritis. <i>Annals of Internal Medicine</i> , 2003, 138, 795.	2.0	105
218	Management of Acute Nonvariceal Upper Gastrointestinal Hemorrhage: Comparison of an American and a Canadian Medical Centre. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2003, 17, 489-495.	1.8	14
219	Do persons with acute, non-variceal upper gi hemorrhage (UGIH) require admission to an icu-monitored bed? Comparison of a canadian and us center. <i>Gastroenterology</i> , 2000, 118, A893.	0.6	1
220	Which low-risk patients with acute, non-variceal upper GI hemorrhage are candidates for early discharge?. <i>Gastroenterology</i> , 2000, 118, A466.	0.6	0